Semaglutide (GLP-1)
Revolutionary Weight Loss & Metabolic Health
A GLP-1 receptor agonist that dramatically reduces appetite and body weight while improving cardiovascular outcomes.
Prescription Required
Can't get Semaglutide (GLP-1) through your GP? These telemedicine providers specialize in peptide therapy.
Everlywell
FDA-approved tesamorelin and comprehensive peptide therapy with at-home testing.
Hone Health
Hormone optimization & peptide therapy for men. At-home testing with physician oversight.
Marek Health
Comprehensive hormone and peptide protocols with detailed blood work analysis.
Everlife.md
Peptide-focused telemedicine platform with personalized protocols and ongoing monitoring.
Peter MD
Telemedicine platform specializing in peptide therapy and hormone optimization.
Defy Medical
Established telemedicine clinic offering peptides, HRT, and regenerative therapies.
Always consult with a licensed physician before starting any peptide therapy.
About Semaglutide (GLP-1)
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has revolutionized the treatment of obesity and type 2 diabetes. Marketed as Ozempic for diabetes and Wegovy for weight loss, it has shown unprecedented efficacy—with average weight loss of 15-20% of body weight in clinical trials. Beyond weight loss, semaglutide demonstrates remarkable cardiovascular benefits, reduced inflammation, and potential neuroprotective effects. It works by mimicking a natural hormone that regulates appetite and blood sugar, making users feel satisfied with less food.
Mechanism of Action
Semaglutide mimics GLP-1, a hormone released by the gut after eating. It slows gastric emptying, increases insulin secretion, decreases glucagon, and acts on brain regions controlling appetite and satiety. The result is dramatically reduced hunger, earlier satiation, and reduced food cravings. Its cardiovascular benefits appear to extend beyond weight loss, with direct effects on inflammation and vascular health.
How Semaglutide (GLP-1) Works in Your Body:
- Target Receptors: Semaglutide (GLP-1) binds to specific receptors that trigger downstream signaling cascades related to its primary benefits.
- Physiological Response: The body responds by modulating natural processes—whether hormone release, tissue repair, or cellular signaling—without replacing endogenous function.
- Timeline: Effects typically begin within a few days, with optimal results seen over the recommended protocol duration.
Dosing Protocol
Frequency
Once weekly (injectable)
Timing
Same day each week, any time of day
Duration
Long-term under medical supervision
Important Notes
Start at 0.25mg weekly and titrate up over 4-8 weeks to maintenance dose (1-2.4mg). Take with or without food. Oral formulation (Rybelsus) available for diabetes.
Clinical Research
4 studies on Semaglutide (GLP-1)
STEP Trials
Participants lost an average of 15-17% body weight over 68 weeks with semaglutide 2.4mg weekly.
New England Journal of Medicine
SELECT Trial
Semaglutide reduced cardiovascular events by 20% in overweight/obese adults without diabetes.
New England Journal of Medicine
SUSTAIN Trials
Semaglutide provided superior blood sugar control compared to other diabetes medications.
The Lancet Diabetes & Endocrinology
Addiction & Behavior
Emerging evidence suggests GLP-1 agonists may reduce alcohol consumption and addictive behaviors.
Journal of Clinical Investigation
Semaglutide (GLP-1) in Practice
Who Semaglutide (GLP-1) is for
Adults with a BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, sleep apnea). Semaglutide is also FDA-approved for type 2 diabetes management. It is most effective for people who have struggled with appetite regulation despite genuine effort with diet and exercise — the central appetite suppression often makes adherence possible for the first time.
Who should avoid it
Personal or family history of medullary thyroid carcinoma or MEN-2 (boxed warning), pregnancy, history of pancreatitis, severe gastroparesis, or active gallbladder disease. People at risk of malnutrition or sarcopenia (elderly, low baseline lean mass) need close monitoring with a structured resistance training and protein intake plan to prevent excessive lean mass loss.
Clinical Context
Semaglutide is a long-acting GLP-1 receptor agonist marketed as Ozempic (diabetes), Wegovy (obesity), and Rybelsus (oral, diabetes). The STEP trials demonstrated 14.9% mean body weight loss at 68 weeks on 2.4 mg weekly Wegovy vs 2.4% on placebo. SUSTAIN trials showed superior A1C reduction vs other diabetes drugs. The standard titration is 0.25 mg weekly for 4 weeks, then 0.5, 1.0, 1.7, and 2.4 mg at 4-week intervals. Slower titration reduces GI side effects.
Common Mistakes to Avoid
Skipping the lean mass protocol
Without resistance training and 1.6 g/kg protein intake, 30-40% of weight lost on semaglutide is lean mass. Treat training and protein as non-negotiable.
Titrating too fast
Most GI side effects (nausea, vomiting, constipation) come from rushing the dose escalation. Stay at each step until tolerated, even if that means 6-8 weeks instead of 4.
Stopping cold turkey
Discontinuation typically leads to ~two-thirds of lost weight returning within a year. Plan a maintenance phase or transition strategy before stopping.
Ignoring micronutrients
Reduced food intake means reduced micronutrient intake. Get a CMP, vitamin D, B12, iron, and electrolytes checked at baseline and every 3-6 months.
GLP-1 Receptor Agonists Compared
| Compound | Compared to | Verdict |
|---|---|---|
| Semaglutide | Tirzepatide | Tirzepatide (GLP-1 + GIP) shows ~21% weight loss vs ~15% — but semaglutide has longer real-world safety data |
| Semaglutide | Liraglutide | Weekly injection vs daily, plus better efficacy (~15% vs ~8% weight loss) |
| Semaglutide | Retatrutide | Retatrutide (triple-agonist, investigational) shows ~24% weight loss in early trials but is not yet approved |
Important Safety Information
Medical Disclaimer: The information provided about Semaglutide (GLP-1) is for educational purposes only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or peptide protocol.
Research Status: While Semaglutide (GLP-1) has shown promising results in research studies, many peptides are still being studied and may not be approved by regulatory bodies like the FDA for specific uses. The research cited represents ongoing scientific investigation.
Individual Variation: Responses to peptides vary significantly between individuals. What works for one person may not work for another. Side effects, while generally mild, can occur and should be monitored closely.
Quality & Sourcing: If you choose to use peptides, ensure you obtain them from reputable, tested sources. Peptide quality, purity, and proper storage are critical for safety and efficacy.
Legal Considerations: Peptide regulations vary by country and jurisdiction. Some peptides may require a prescription or may have restrictions on their use. Research the laws in your area before obtaining or using peptides.